VYN201 Gel for Vitiligo
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
Do I need to stop taking my current medications for the trial?
You will need to stop taking any medications used to treat vitiligo during the trial. However, if you are taking other medications for different conditions, you can continue them as long as your regimen is stable from the start of the trial to its completion.
What safety data is available for VYN201 Gel (repibresib) in treating vitiligo?
The provided research does not contain specific safety data for VYN201 Gel (repibresib) in the treatment of vitiligo. The studies focus on other treatments and their safety profiles, such as ruxolitinib cream, excimer light, targeted UVB, and other drugs associated with vitiligo. Therefore, no direct safety data for VYN201 Gel is available in the provided research.12345
Is VYN201 Gel a promising drug for vitiligo?
What data supports the idea that VYN201 Gel for Vitiligo is an effective treatment?
Are You a Good Fit for This Trial?
This trial is for individuals with non-segmental vitiligo, a condition where skin loses its pigment. Details about who can join or reasons why someone might not be eligible are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VYN201 Gel or placebo once daily for 24 weeks in a double-blind, vehicle-controlled period
Treatment Extension
Participants continue treatment with VYN201 Gel for an additional 28 weeks, maintaining the blind
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VYN201 Gel
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vyne Therapeutics Inc.
Lead Sponsor